文献速递产科母胎医学

低置胎盘患者的产后出血:系统综述与Meta分析

Postpartum Hemorrhage in Patients With a Low-Lying Placenta: A Systematic Review and Meta-analysis.
PubMed 文献 · Obstet Gynecol · 2025-06-05

该系统综述与Meta分析纳入21项研究(低置胎盘3704例,正常胎盘2555例),发现任何孕周的低置胎盘均显著增加产后出血风险(RR 2.10,95%CI 1.02-4.35,P=.05,I²=0.0%)。低置胎盘1-20 mm组的产后出血发生率为16.0%,正常胎盘组为5.8%;胎盘距宫颈内口1-10 mm组与11-20 mm组的产后出血风险无显著差异(RR 0.97,95%CI 0.67-1.41,P=.84,I²=0.0%)。低置胎盘病例中胎盘植入谱系疾病发生率为9.0%。

要点

  • 产前诊断低置胎盘与产后出血风险增加约两倍相关(RR 2.10,95%CI 1.02-4.35)。
  • 低置胎盘1-10 mm组产后出血发生率为16.6%,11-20 mm组为17.5%,两组无显著差异。
  • 低置胎盘病例中胎盘植入谱系疾病发生率为9.0%(95%CI 4.7-16.8%,I²=89.9%)。

核心结论

  • 产前诊断低置胎盘与正常胎盘相比,产后出血风险增加约两倍(RR 2.10,95%CI 1.02-4.35,P=.05,I²=0.0%)。
  • 低置胎盘1-10 mm组产后出血汇总比例为16.6%,11-20 mm组为17.5%,两组无显著差异(RR 0.97,95%CI 0.67-1.41,P=.84,I²=0.0%)。
  • 本Meta分析首次量化低置胎盘相关的产后出血风险,强调需要对低置胎盘妊娠进行严密监测和分娩管理以减轻产后出血对母亲疾病的负担。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、ClinicalTrials.gov、EMBASE和Web of Science从建库至2024年4月30日。
  • 共筛选3700条结果,纳入21项研究,低置胎盘患者3704例,正常胎盘2555例。
  • 排除2000年前发表的研究以减少超声敏感性偏倚;由三名评价员独立使用纽卡斯尔-渥太华量表进行数据提取和质量评价。
  • 研究纳入标准采用PICO框架:人群为单胎妊娠,干预为低置胎盘,对照为正常胎盘,结局为产后出血和胎盘植入谱系疾病。
  • 系统综述注册号:PROSPERO,CRD42024558043。

主要发现

  • 任何孕周的低置胎盘与非低置胎盘相比,产后出血风险显著增加(RR 2.10,95%CI 1.02-4.35,P=.05,I²=0.0%)。
  • 低置胎盘1-20 mm组产后出血发生率为16.0%(95%CI 10.3-24.1%,I²=93.3%),非低置胎盘组为5.8%(95%CI 3.8-8.8%,I²=79.9%)。
  • 按临床有意义分层,低置胎盘已消退组产后出血发生率为8%(95%CI 4.1-16.3%,I²=85.0%),未消退组为29.2%(95%CI 19.0-42.0%,I²=70.5%),非低置胎盘组为5.8%(95%CI 3.8-8.8%,I²=79.9%)。
  • 距宫颈内口小于2 cm时,低置胎盘1-10 mm组产后出血发生率为16.6%(95%CI 9.2-28.3%,I²=78.4%),11-20 mm组为17.5%(95%CI 8.8-31.7%,I²=92.2%),两组风险无显著差异(RR 0.97,95%CI 0.67-1.41,P=.84,I²=0.0%)。
  • 胎盘植入谱系疾病影响所有低置胎盘病例的9.0%(95%CI 4.7-16.8%,I²=89.9%)。

临床怎么用

  • 原文结论强调需要对低置胎盘妊娠进行严密监测和分娩管理,以减轻产后出血对母亲疾病的负担。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We hypothesized that a second- or third-trimester diagnosis of low-lying placenta imparts underappreciated risk for postpartum hemorrhage (PPH) and placenta accreta spectrum (PAS). To quantify this risk and to assess whether it varies by the specific distance of the placenta from the cervical os and low-lying placenta resolution status, we conducted a systematic review and meta-analysis. DATA SOURCES: Systematic searches were conducted in PubMed, ClinicalTrials.gov , EMBASE, and Web of Science from database inception to April 30, 2024. METHODS OF STUDY SELECTION: A total of 3,700 results were screened for relevance with the PICO framework: population-singleton pregnancies; intervention-low-lying placenta; comparators-normal placentation; and outcomes-PPH and PAS. Studies published before 2000 were excluded to minimize bias from ultrasound sensitivity. TABULATION, INTEGRATION, AND RESULTS: Twenty-one studies (3,704 patients with low-lying placenta, 2,555 with normal placentation) were included. Data extraction and quality assessment with the Newcastle-Ottawa Scale were performed independently by three reviewers. At any gestational age, low-lying placenta imparted a significant PPH risk (risk ratio [RR] 2.10, 95% CI, 1.02-4.35, P =.05, I2 =0.0%) compared with non-low-lying placenta. The incidence of PPH was 16.0% (95% CI, 10.3-24.1%, I2 =93.3%) in low-lying placenta 1-20 mm compared with 5.8% (95% CI, 3.8-8.8%, I2 =79.9%) in non-low-lying placenta. When parsed by clinically meaningfully strata, a high incidence of PPH persisted with resolved low-lying placenta (resolved: 8%, 95% CI, 4.1-16.3%, I2 =85.0%; unresolved: 29.2%, 95% CI, 19.0-42.0%, I2 =70.5%; non-low-lying placenta: 5.8%, 95% CI, 3.8-8.8%, I2 =79.9%) with no difference in PPH risk at less than 2 cm from the os (low-lying placenta 1-10 mm: 16.6%, 95% CI, 9.2-28.3%, I2 =78.4%; low-lying placenta 11-20 mm: 17.5%, 95% CI, 8.8-31.7%, I2 =92.2%; RR 0.97, 95% CI, 0.67-1.41, P =.84, I2 =0.0%). An important finding is that PAS disorders affected 9.0% (95% CI, 4.7-16.8%, I2 =89.9%) of all low-lying placenta cases. CONCLUSION: Antepartum diagnosis of low-lying placenta is associated with a twofold increased risk of PPH compared with normal placentation. The pooled proportions of PPH were 16.6% in the 1-10 mm group and 17.5% in the 11-20 mm low-lying placenta group, with no significant difference. This meta-analysis is the first to quantify the risk of PPH associated with low-lying placenta, emphasizing the need for rigorous monitoring and delivery management of pregnancies with low-lying placenta to mitigate the burden of PPH on maternal morbidity. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42024558043.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Bonanni G, Lopez MC, Tarchi SM, et al. Postpartum Hemorrhage in Patients With a Low-Lying Placenta: A Systematic Review and Meta-analysis. Obstet Gynecol. 2025. PMID: 40472373. doi:10.1097/AOG.0000000000005956

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。